2002
DOI: 10.1007/bf02988652
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of [18F]FDG-PET andl-3[123I]-iodo-α-methyl tyrosine (I-123 IMT)-SPECT in primary lung cancer

Abstract: Despite the limited number of patients it may be concluded that IMT-SPECT as well as FDG-PET are suited to correctly diagnose lung cancer. Nevertheless, FDG-PET, if available, seems to be better suited because of the higher tumor/background ratio and better resolution.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2005
2005
2022
2022

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 1 publication
0
1
0
1
Order By: Relevance
“…However, the available data on the usefulness of IMT-SPECT for detection of extracranial tumours are sparse. According to some studies with small patient populations, there is an evidence of high IMT uptake in lung cancer and soft-tissue tumours [23,[34][35][36][37], whereas the results for melanomas and carcinoid tumours are less encouraging [38,39]. The feasibility of IMT-SPECT for the detection of head and neck squamous cell carcinoma was first investigated by Flamen et al [23].…”
Section: Clinical Considerationsmentioning
confidence: 99%
“…However, the available data on the usefulness of IMT-SPECT for detection of extracranial tumours are sparse. According to some studies with small patient populations, there is an evidence of high IMT uptake in lung cancer and soft-tissue tumours [23,[34][35][36][37], whereas the results for melanomas and carcinoid tumours are less encouraging [38,39]. The feasibility of IMT-SPECT for the detection of head and neck squamous cell carcinoma was first investigated by Flamen et al [23].…”
Section: Clinical Considerationsmentioning
confidence: 99%
“…Bei der Gruppe der Technetium-markierten Pharmaka wird das Radionuklid durch einen biologischen Vektor selektiv an sein spezifisches Ziel geleitet. Ein klinisches Beispiel für die diagnostische Bildgebung ist das 99 m Tc-Arcitumomab (CEA-SCAN), bei dem 99m Tc ein Fragment von Arcitumomab bindet, einem monoklonalen Antikörper, der carcinoembryonales Antigen (CEA) erkennt, das bei kolorektalen Karzinomen überexprimiert ist 19 20 . Im Laufe der Jahre wurden mehrere rezeptorspezifische Radiopharmazeutika entwickelt, bei denen mehrere stabile Kernstrukturen für Tc durch „mehrzähnige“ Liganden stabilisiert werden, die N-, S-, P- und O-Donoratome einschließen und an einen biomolekularen Vektor (BM) gebunden sind.…”
Section: Theoretische Grundlagen Der Radiopharmazieunclassified